Sivextro (Tedizolid Phosphate) Patent Expiration, LOE Window & CMS Spending

Sivextro (Tedizolid Phosphate) by Merck & Co.: FDA Orange Book core substance LOE 2030-12-31, 0 AB generics, $19.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN205435 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2030-12-31
Last Listed Patent or Exclusivity Date2030-12-31
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$19.3M
2024 Medicare Part D Spend$16.5M
2024 Medicaid Spend$2.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.